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Background: Tumor cells in the blood of patients with metastatic carcinomas are associated with poor survival.
Knowledge of the cells’ genetic make-up can help to guide targeted therapy. We evaluated the efficiency and
quality of isolation and amplification of DNA from single circulating tumor cells (CTC).
Methods: The efficiency of the procedure was determined by spiking blood with SKBR-3 cells, enrichment with the
CellSearch system, followed by single cell sorting by fluorescence-activated cell sorting (FACS) and whole genome
amplification. A selection of single cell DNA from fixed and unfixed SKBR-3 cells was exome sequenced and the
DNA quality analyzed. Single CTC from patients with lung cancer were used to demonstrate the potential of single
CTC molecular characterization.
Results: The overall efficiency of the procedure from spiked cell to amplified DNA was approximately 20%. Losses
attributed to the CellSearch system were around 20%, transfer to FACS around 25%, sorting around 5% and DNA
amplification around 25%. Exome sequencing revealed that the quality of the DNA was affected by the fixation of
the cells, amplification, and the low starting quantity of DNA. A single fixed cell had an average coverage at 20×
depth of 30% when sequencing to an average of 40× depth, whereas a single unfixed cell had 45% coverage.
GenomiPhi-amplified genomic DNA had a coverage of 72% versus a coverage of 87% of genomic DNA.
Twenty-one percent of the CTC from patients with lung cancer identified by the CellSearch system could be
isolated individually and amplified.
Conclusions: CTC enriched by the CellSearch system were sorted by FACS, and DNA retrieved and amplified with
an overall efficiency of 20%. Analysis of the sequencing data showed that this DNA could be used for variant
calling, but not for quantitative measurements such as copy number detection. Close to 55% of the exome of
single SKBR-3 cells were successfully sequenced to 20× depth making it possible to call 72% of the variants. The
overall coverage was reduced to 30% at 20× depth, making it possible to call 56% of the variants in CellSave-fixed
cells.Background
Treatment options for patients with metastatic carcin-
omas are increasing rapidly and create a concomitant
need for companion diagnostics to establish the therapy
that is most likely to be effective. For a targeted therapy
to be effective, its target needs to be present in the
tumor cells. However, cancer cells are heterogeneous
both within and between patients, forcing the need for* Correspondence: j.f.swennenhuis@utwente.nl
1Department of Medical Cell BioPhysics, MIRA Institute, University of Twente,
Carre Room C4437, Hallenweg 23, 7522 NH Enschede, The Netherlands
Full list of author information is available at the end of the article
© 2013 Swennenhuis et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumindividual characterization of the tumor cells. Moreover,
during the course of the disease, resistance to therapy
can develop and a timely detection and search for alter-
native therapies is desirable. Tumor biopsies are difficult
if not impossible to obtain at the time a new line of ther-
apy is indicated. Tumor cells from solid tumors are shed
into the circulation and these circulating tumor cells
(CTC) may serve as a liquid biopsy to guide therapy.
The presence of CTC in patients with metastatic carcin-
omas is associated with poor survival, with a greater load
indicating a worse prognosis [1-5]. Treatment targets
can be assessed on CTC [6-9]; however, the frequency ofentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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obtain a sufficient number of CTC to evaluate all poten-
tial treatment targets. The ability to isolate and amplify
DNA from the individual CTC would overcome some of
these challenges. We evaluated the feasibility of DNA
amplification after fluorescence-activated cell sorting
(FACS) of CTC obtained by what is currently the only
clinically validated system for CTC enumeration [12].Methods
Patient and control samples
The patient samples came from 10 patients with meta-
static small cell lung cancer or metastatic non-small-
cell lung cancer. The control samples were taken from
healthy volunteers aged 20 to 55 years. From each
participant, 10 ml of blood was drawn in a CellSave
(Veridex LLC, Raritan, NJ, USA) or ethylenediamine-
tetraacetic acid (EDTA; Beckton Dickinson, Franklin
Lanes, NJ, USA) evacuated blood draw tube. The
healthy volunteers provided informed consent prior to
donating blood under a study protocol approved by
the Ethics Committee (METC Twente). All patients
consented to provide blood for the study, and the study
protocol was approved by the ethics review commit-
tee from University Medical Center Groningen, The
Netherlands.Circulating tumor cell identification and preparation for
cell sorting
Aliquots of 7.5 ml of blood were processed on a
CellTracks Autoprep using the CellSearch Circulating
Tumor cell kit (Veridex LLC) [12]. The enriched cells
were fluorescently labeled with the nucleic acid dye 4ʹ6-
diamidino-2-phenylindole (DAPI) and the monoclonal
antibodies directed against CD45 fluorescently labeled
with allophycocyanin (APC) and directed against cyto-
keratins (CKs) labeled with phycoerythrin. For CTC
enumeration, the cartridges were placed on a CellTracks
Analyzer II or CellSpotter for image acquisition and
image review (Veridex LLC) [11,12]. After scanning, the
cartridges were stored at 4°C for a maximum of 24 hours
before further processing. The content of the cartridge
was transferred to a 12 × 35 mm flowtube and washed
twice with 200 μl dilution buffer to ensure removal of
the majority of cells from the cartridge. To ensure suffi-
cient fluorescent nucleic acid signals, 2 μg/ml Hoechst
33342 (Molecular Probes, Eugene, OR, USA; cat. H3570)
was added for 15 minutes at 37°C prior to cell sorting.
In addition, 2 × 104 beads (BD Biosciences, Jan Jose, CA,
USA; cat. 345249) were added to ensure correct instru-
ment settings and to serve as negative controls for cell
sorting and DNA amplification.Single cell sorting
A FACSARIA II (BD Biosciences) equipped with a
375 nm, 488 nm and 633 nm laser and single cell de-
posit unit was used for single CTC sorting. Cells were
sorted into 384 well plates (BioRad, Hercules, CA, USA;
cat. HSP3805). The instrument was calibrated using
CS&T beads (Beckton Dickinson; cat. 641412) before
use. Before sorting, the sort gates and the number of
cells and beads to be sorted into the 384 wells were set.
For single cell sorting, 20 beads were also sorted into
the well. To serve as positive and negative controls for
DNA amplification, for each patient, 10 single leukocytes
(CD45+, Hoechst+), five wells with 20 beads were sorted
and five wells were left empty. Wells that had DNA
amplification initiation within 95 minutes were regarded
as positive.Efficiency of DNA amplification
Cells from the breast cancer cell line SKBR-3 were used
to monitor the individual amplification reactions of both
single and multiple cells compared to the amplification
of background DNA. After trypsinization, the cells were
suspended in 9 ml of culture medium (Dulbecco’s modi-
fied Eagle’s medium; Sigma Aldrich, St Louis, MO, US;
cat. D5796), 1% penicillin/streptomycin (Sigma Aldrich;
cat. P4333), 2 mM L-glutamine (Sigma Aldrich; cat.
G7513) and 10% fetal calf serum (Sigma Aldrich; cat.
F4135). This suspension was transferred to a CellSave
tube. After 24 hours, 1 ml of this suspension was stained
with 2 μg/ml Hoechst 33342 (Invitrogen, Grand Island,
NY, USA; cat. H3570) for 15 minutes at 37°C. Next, 2 ×
104 beads (BD; cat. 345249) were added to the cells and
100, 10, 1 and 0 SKBR-3 cells and 20 beads were sorted
into a 384-well plate. Five experiments were performed
for each spike level except for the single cells, for which
10 were performed.
After sorting, the wells were treated with proteinase K
by incubating with 1 μl 0.625% proteinase K (Sigma
Aldrich; cat. P4850) in 10 mM Tris-HCl pH 7.4 for
1 hour at 50°C. The proteinase K was inactivated by in-
cubating for 10 minutes at 96°C. After this step, 5 μl of
an amplification mix containing Evagreen, a double-
stranded DNA dye (Biotium, Hayward, CA, USA; cat.
31000), was added to each well. The amplification mix
consisted of components from the GE Illustra Genomi-
Phi DNA amplification kit (GE Healthcare Life Sciences,
Waukesha, WI, USA; cat. 25-6600-31) combined with
Evagreen to monitor the reaction. The composition of
the mix for each well was 1.75 μl sample buffer, 2.25 μl
reaction buffer, 0.25 μl enzyme, 0.125 μl Evagreen, and
0.625 μl H2O. The plate was incubated for 250 minutes at
30°C in a BioRad CFX 384 quantitative PCR instrument
while measuring the fluorescence every 5 minutes. After
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65°C and the plates stored at -20°C.
Sample quality analysis of fixed cells, unfixed cells and
isolated DNA by exome sequencing
SKBR-3 cells were trypsinized, suspended in culture
medium and the genomic DNA isolated using the
Promega Wizard SV Genomic DNA Purification System
(Promega, Madison, WI, USA); cat. A1120). The cells
were stained with Hoechst 33342 and individually
placed in the wells of a 30-well epoxy-coated microscope
slide (Menzel-Gläser, Braunschweig, Germany; cat
X1XER312B) using a micromanipulator (Eppendorf,
Hamburg, Germany). Confirmation that the wells in-
deed contained a single cell was obtained by fluores-
cence microscopy. Control wells were filled with 50
CellSave-fixed or 50 unfixed cells. Fixed cells were
lysed by incubating with 1 μl 0.625% proteinase K in
10 mM Tris-HCl pH 7.4 for 1 minute, 10 minutes,
30 minutes or 1 hour at 50°C. The proteinase K was
inactivated as above, by incubating for 10 minutes at
96°C. The unfixed cells were lysed by adding 1 μl lysis
buffer (400 mM KOH, 25 mM EDTA, 100 mM dithio-
treitol) to the cells and incubating for 10 minutes on
ice, after which 1 μl neutralization buffer (0.4 μl 1 M
HCl and 0.6 μl 1 M Tris-HCl, pH 7.5, premixed) was
added. DNA was amplified as described above except
for the addition of Evagreen. Samples were incubated
for 2 hours at 30°C in a humidified chamber. Separ-
ately, 10 ng of the genomic DNA was amplified in a
tube in 5 μl amplification mixture. To obtain enough
DNA for sequencing, the initial amplifications samples
were transferred to a vial and reamplified in a 100 μl
amplification mixture using the same kit and reagent
composition for 2 hours at 30°C. The final product was
purified using a Qiagen PCR Purification Kit (Qiagen
GmbH, Hilden, Germany). Genomic DNA (×1), amplified
genomic DNA (×1), amplified DNA of 50 cells (×3) and
amplified DNA of single cells (×7) were used for Illumina
sequencing (Genome Analyzer IIx (GAIIx); Illumina,
(San Diego, CA, USA)).
Exome sequencing
Exomes were captured using Illumina’s TruSeq Exome
Enrichment Kit. The TruSeq capture regions encom-
passed 62 Mb, including 20,794 genes (201,121 exons).
According to the RefGene definitions, 94.4% of exonic
regions, 83.9% of 5′-untranslated regions and 91.9% of
3′-untranslated regions were included in the targeted
capture. Pre-enrichment DNA libraries were constructed
according to the standard protocol from Illumina’s TruSeq
DNA Sample Preparation Guide. A 200- to 300-bp band
was gel-selected for each library and exome enrichment
was performed according to Illumina’s TruSeq ExomeEnrichment Guide. Two rounds of biotinylated bait-based
hybridizations were performed, followed by binding
with streptavidin magnetic beads, a washing step, and
an elution step. A 10-cycle PCR enrichment was per-
formed after the second elution and the enriched libraries
were subjected to Illumina sequencing (GAIIx). Libraries
were denatured with sodium hydroxide and loaded onto
an Illumina cBot for cluster generation according to the
manufacturer’s recommended protocols. Paired-end se-
quencing (2 × 75 bp) was performed using TruSeq SBS
kits (Illumina). A single lane was used for each sample.
The Burrows-Wheeler aligner [13] was used to align the
raw reads from each sequencing lane (in fastq format)
to the human reference genome (NCBI37/hg19) using
default parameters. Aligned reads were processed and
sorted using SAMtools [14] and PCR duplicates were
marked with Picard MarkDuplicates [15]. Base recali-
bration, local realignment around indels and single
nucleotide variant calling were performed using the
GenomeAnalysis ToolKit [16]. Basic statistics for coverage
depth and variant composition were performed using
the BEDtools suite [17], VCFtools [18] and custom Perl
scripts.
The sequence data have been deposited in the European




Figure 1 shows typical scatter plots from a flow-cytometric
measurement of the contents of a CellSearch cartridge after
processing 7.5 ml of blood spiked with 50 SKBR-3 cells.
Panel A shows the DAPI/Hoechst staining and the gate to
identify the beads is depicted in pink; the gate used to iden-
tify nucleated cells is also indicated. Panel B shows the
CD45-APC staining versus the CK-PE staining of the
DAPI/Hoechst + events. In this panel, the gates used to
identify CTC (depicted in red) and leukocytes (depicted in
green) are indicated. In this example, 41 events are identi-
fied as CD45+, CK- and DAPI + leukocytes, and 26 events
as CD45-, CK + and DAPI +CTC. In this case, the CTC
were the SKBR-3 cells that were spiked into the blood; 26
of the 50 (52%) spiked SKBR-3 cells were recovered. The
shape and position of the CTC gate were set such that as
few as possible DAPI + events appear in this gate when pro-
cessing the blood of healthy donors while capturing as
many CTC as possible from positive patient samples. Table
S5 in Additional file 1 contains the results of eight healthy
control samples analyzed with these settings after a Cell-
Search run. On average, these samples had 1.6 ±1.1 events
in the CTC gate. In panels C, E and G, the CD45-APC,
CK-PE scatterplots of samples from three patients with
metastatic lung cancer are shown. A large variation in the
number of CTC as well as the number of leukocytes in
Figure 1 (See legend on next page.)
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Figure 1 Flow-cytometric analysis of CellSearch-enriched circulating tumor cells and real-time whole genome amplification of single-sorted
leukocytes and circulating tumor cells. Panels (A) and (B) show the sort gates to identify and sort single CTC, single leukocytes and beads. Panels
(C) (Table 1, patient 7), (E) (Table 1, patient 1) and (G) (Table 1, patient 2) show the analysis and sort gates of three patients with lung cancer. Panels
(D), (F) and (H) show the corresponding real-time DNA amplification of the individual sorted cells. The curves show the Evagreen fluorescence of the
whole genome amplification reaction mixes in time. APC = allophycocyanin, PE = phycoerythrin, SSC = sidescatter.
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CD45+, CK+, DAPI + events can be observed between the
leukocytes and the CTC gates that vary in frequency.
Efficiency of DNA amplification
One of the main challenges in single-cell whole genome
amplification (WGA) is quality control. Most amplifica-
tion reactions are so sensitive that any trace of DNA in
wells not containing a cell will be amplified to a
maximum yield that is often indistinguishable from
wells containing cells, even when using quality control
methods such as gel electrophoresis or quantitative PCR.
However, a simple method to check for the presence of
a cell in a well is the addition of a fluorescent nucleic
acid dye to the amplification reaction that can be
followed in real time as shown in Figure 2. This figure
shows the real-time monitoring of DNA amplifications
in wells into which 100, 10, 1 and 0 SKBR-3 cells were
sorted. Twenty beads were also sorted into each well.
Besides acting as a control, the volume of the droplets
serve as a carrier for the cell to move to the bottom of
the well. The higher amount of DNA in wells with more
cells can be clearly distinguished and, most importantly,Figure 2 DNA amplification SKBR-3 sorted into a 384-well plate.
Pink indicates 100 SKBR-3 cells plus 20 beads. Blue indicates 10
SKBR-3 cells plus 20 beads. Red indicates one SKBR-3 cell plus 20
beads. Green indicates 0 SKBR-3 cells and 20 beads. Black indicates
an empty well. Cells were lysed by treating for 1 hour at 50°C with
1 μl protein K solution, 10 minutes inactivation at 96°C and cooled
to 4°C. Whole genome amplification mix (5 μl) was added and
incubated for 250 minutes at 30°C on a BioRad CFX 384 quantitative
PCR machine while measuring fluorescence every 5 minutes. The
two arrows point to the amplification of two single cells that did
not show any amplification.the wells containing one cell can easily be distinguished
from the negative controls. In two of the 10 wells (indi-
cated by arrows) in which a single SKBR-3 cell was
sorted, the amplification occurred at the same time as
the negative controls, indicating that either the cell was
not sorted or not lysed correctly. The negative controls
all amplified at around 90 minutes regardless of whether
they contained beads or not. One well with a single
SKBR-3 did not show any amplification.
Yield and reproducibility of circulating tumor cell
isolation and whole genome amplification of spiked
samples
Since CTC are rare in most patients, the goal is to keep
the loss of cells during the procedure as low as possible.
To quantify the yield and illustrate the reproducibility of
each of the important steps, 500, 50 and 5 SKBR-3 cells
were placed in 7.5 ml of blood. The blood was processed
by the CellSearch system, transferred and identified by
FACS, sorted by FACS, then DNA isolated and amplified
by WGA. Figure 3 shows the yield of each of these steps.
The efficiency of the CellSearch system to recover
SKBR-3 cells was approximately 80% and close to theFigure 3 Yields of each of the steps for whole genome
amplification. SKBR-3 cells were sorted into aliquots of 7.5 ml of
blood containing 500, 50 and 5 cells, and enriched and enumerated
by CellSearch. The contents of the CellSearch cartridge was placed
in a FACS tube and SKBR-3 cells sorted into a 384-well plate. On
each well, a GE GenomiPhi amplification reaction was performed in
the presence of Evagreen. The yield of each step in the procedure
was determined and plotted as a percentage of the starting amount.
Each experiment was performed in triplicate except for the 5-cell
sort, which was done six times. FACS, fluorescence-activated
cell sorting.
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of the spiked SKBR-3 cells were then found back in the
DAPI+, CK+, CD45- gate and about 40% of the spiked
SKBR-3 cells were sorted. The yield at the 500 cell spikes
was lower as compared to the 50 and 5 cell spikes. The
percentage of wells that resulted in an efficient amplifi-
cation by WGA was approximately 20% with the largest
variation at the 5 cell spike level. More detailed informa-
tion on the yield and reproducibility tests can be found
in Table S1 in Additional file 1.
Efficiency of circulating tumor cell isolation and whole
genome amplification in patients with non-lung cancer
The number of CTC in patients with metastatic small
cell and non-small-cell lung cancer varies greatly [1,2].
To determine the efficiency at which CTC can be iso-
lated and individually sorted and the DNA amplified,
blood samples from 10 patients with lung cancer were
processed using the CellSearch system. The number of
CTC identified in 7.5 ml of blood, the percentage of
those cells that were identified as CTC by FACS and
sorted, as well as the number of single CTC successfully
amplified was determined (Table 1). An amplification
was regarded as successful when a well had a cycle
threshold (Ct) lower than the cutoff of 95 minutes. From
the control samples that were done, two out of 50 nega-
tive controls with 20 beads sorted from the same sam-
ples were below this cutoff. None of the 50 empty
negative controls was below this cutoff. Of the single
leukocyte controls from the same patients, 85% (n = 100)Table 1 CellSearch circulating tumor cell counts of samples fr
number of circulating tumor cells identified and sorted by flu
amplified
Patient Disease CellSearch- FACS-
identified identifie
CTC CTC
1 SCLC 81 34 (42%
2 SCLC 11 2 (18%)
3 SCLC 3 3 (100%
4 NSCLC 4 2 (50%)
5a NSCLC 8 6 (75%)
6 SCLC 37 6 (16%)
7 SCLC 23 9 (39%)
8 SCLC 41 17 (41%
9 SCLC 44 3 (6.8%)
10 NSCLC 0 1
Total 252 83 (33%
aThe first five samples were used to optimize the gates for patient CTC sorting. Afte
shows the CTC identified after the gates were changed, showing the number of CT
cells could be higher than 100% because there were more cells in the gate due to
serve as a control. CTC, circulating tumor cells; FACS, fluorescence-activated cell sor
white blood cells.were below this cutoff. Panels C, E and G in Figure 1
show three examples of the sort gates used and the real-
time DNA amplification plots from these patients are
shown in panels D, F and H. From the nine CTC identi-
fied by FACS in panel C, six showed a successful DNA
amplification whereas nine of the ten leukocytes ampli-
fied successfully, as shown in panel D. From the 34 CTC
identified by FACS in panel E, 17 showed a successful
DNA amplification whereas all of the 10 leukocytes
amplified successfully, as shown in panel F. From the
two CTC identified by FACS in panel G, two showed a
successful DNA amplification and also all of the ten
leukocytes amplified successfully, as shown in panel H.
Quality of the whole genome amplified DNA by exome
sequencing
DNA produced by WGA kits is likely to contain aberra-
tions introduced by the amplification method. The amp-
lified genome of single cells is even more prone to
aberrations because of the low starting copy number.
DNA derived from single, multiple and genomic DNA
from SKBR-3 cells was used for exome sequencing and
analysis to check for the quality and representation of
the exome. The fraction of bases mapping to the tar-
geted exonic regions was fairly stable for all samples
(approximately 60%) and the overall coverage depth per
sample was sufficient for reliable variant calling. The
coverage depth distribution (Figure 4A) shows that the
fraction of uncovered bases at low coverage depth in-
creased dramatically in all samples that had undergoneom 10 patients with metastatic lung cancer, and the
orescence-activated cell sorting and successfully
FACS- DNA- DNA-
d sorted amplified amplified
CTC CTC WBC (%)
) 17 (21%) 17 (21%) 10 (100%)
3 (27%) 2 (18%) 10 (100%)
) 2 (67%) 2 (76%) 7 (70%)
9 (225%) 0 (0%) 10 (100%)
32 (400%) 3 (38%) 2 (20%)
5 (14%) 4 (11%) 10 (100%)
9 (39%) 6 (26%) 9 (90%)
) 17 (41%) 16 (39%) 8 (80%)
2 (4.5%) 2 (4.5%) 9 (90%)
1 1 10 (100%)
) 97 (39%) 52 (21%) 85 (85%)
r five samples, the gates were set and not changed anymore. This table
C that would have been sorted with these gate settings. The number of sorted
the initial gate setting. For each patient, 10 leukocytes were also sorted to
ting; NSCLC: non-small-cell lung cancer; SCLC: small cell lung cancer; WBC,
Figure 4 Coverage depth. (A) Fraction of bases with indicated coverage depth of genomic DNA (dark blue with mark, n = 1), amplified
genomic DNA (red, n = 1), amplified DNA from multiple unfixed cells (yellow, n = 1), amplified DNA from multiple fixed cells (green, n = 2), and
single unfixed (purple, n = 3) and fixed cells (blue, n = 4). (B) Cumulative fraction of the exome that was covered above coverage depths for the
same samples as (A). The dotted lines indicate the standard deviations. The lines from 50 cells fixed (green) and 50 cells unfixed (yellow) mostly
overlap. gDNA, genomic DNA; WGA, whole genome amplification.
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difference in coverage from fixed and unfixed cells. For
samples amplified from single cells, there was a higher
fraction of low or uncovered bases, highest for the DNA
amplified from fixed single cells. Figure 4B shows the
total coverage above specific coverage depths.
In the genomic SKBR-3 DNA, 42,225 variants to the
human reference genome (NCBI37/hg19) were found. In
the WGA of this DNA, 36,339 variants were found, of
which 75.3% matched the variants found in the isolated
genomic DNA (Figure 5A,C). About the same number
of variants (38,752) can be found in the DNA produced
from the 50 cells, of which 78.1% matched the genomic
DNA. In the single-cell samples, the number of match-
ing variants decreased to 23,847 (56.5% matching) forunfixed cells and 15,071 (35.7% matching) for fixed cells.
The false discovery rate was around 6,000 (range 4,534
to 6,438) for the multi-cell samples and the single-cell
unfixed samples (Figure 5B). The single-cell fixed sam-
ples all had a clearly higher false discovery rate (range
8,267 to 9,211). In the single-cell samples, the ratio of
heterozygous to homozygous variants also decreased
(Figure 5D). More detailed information is provided on
the variant calling and the false negatives in Tables S2
and S3 in Additional file 1.
Discussion
To determine the type of cancer therapy with the
greatest likelihood of success, tumor cells representing
the cancer must be available at the time of therapy
Figure 5 Plots of the variants called in the DNA samples. (A) Total number of variants found in the samples. (B) False discovery rate - the
number of variants that were not in the genomic DNA. (C) The number of variants that match with the genomic DNA. (D) Heterogeneity to
homogeneity ratio of the variants found. X-axis abbreviations: gDNA = genomic DNA, WGAgDNA =Whole genome amplification done on gDNA,
WGA 50 cell whole genome amplification done on 50 cells, NF = not fixed, F = fixed.
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ledge of the heterogeneity of tumor cells with respect to the
treatment targets is of great importance. Characterization
at the single-cell level is important to determine the extentof this heterogeneity. The ability to isolate tumor cells cir-
culating in the blood presents an opportunity for a liquid
biopsy throughout the course of the disease, and has
spurred the development of a variety of technologies
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rare and the only clinically validated system to capture
these cells is the CellSearch system. After CTC enrichment,
100 to 10,000 leukocytes remain among the CTC and vari-
ous techniques can be used to isolate a single CTC from
these enriched cell suspensions. Examples are the use of a
micromanipulator [19] and the use of a DEPArray [20] after
the cells have been removed from the cartridge and identi-
fied by fluorescence microscopy. Laser microdissection of
single cells [21] is also an option, but no reported studies
using this in combination with CellSearch exist to our
knowledge. In our study, we evaluated the use of FACS to
isolate single CTC from CTC-enriched cell suspensions.
Each of these techniques has its advantages and disadvan-
tages, and the choice is dictated by the availability of the
equipment in the laboratory, the time and experience
needed to isolate the single cells, and the costs and the effi-
ciency at which CTC can be obtained from an enriched cell
population.
All the techniques used to isolate CTC suffer from cell
loss during the transfer steps. In our experiments, we
lost 40% to 50% of the cells identified by the CellSearch
system as CTC by FACS. This is still a favorable per-
formance as compared to the cell losses we incurred
using a micromanipulator (data not shown). The cell
losses described are in a model system in which a known
number of tumor cells are spiked in blood and the losses
at each step can be determined. It is difficult, if not im-
possible, to determine losses when using patient blood
because the number of CTC in the blood is not known.
However, we can assess the number of CTC detected by
the CellSearch system and determine the percentage of
CTC recovered and the number of CTC from which the
DNA can be successfully amplified. Successful amplifica-
tion of the individually sorted CTC in samples from pa-
tients with lung cancer varied greatly, suggesting that
the ‘quality’ of the CTC is an important factor. A likely
cause of the variability is that the DNA cannot be
successfully amplified when the CTC are undergoing
apoptosis. A similar observation was made for CTC that
were examined by fluorescence in situ hybridization [8].
Additional markers will need to be developed that
can ensure the identified CTC have a high likelihood of
achieving successful DNA/RNA isolation and amplification.
The processing time to obtain amplified DNA from
single cells in general is around 48 hours. Since CTC are
rare and in some cases fragile, EDTA blood is not opti-
mal for conservation of such cells. For this reason, the
CellSave tube was developed to keep the CTC stable for
up to 96 hours before processing. The disadvantage of
this fixation method is that DNA needs to be released
from the fixed proteins of the cell for optimal amplifica-
tion of the generated products. We used various incuba-
tion times for proteinase K treatment to optimize thesample pretreatment, measured in the quality of single-
cell WGA DNA from cells exposed to CellSave by
exome sequencing. However, this did not lead to any
difference in the DNA sequence data. From earlier ex-
periments, we know that treatment with proteinase K is
necessary to achieve any amplification product from the
single fixed cells. From this, we conclude that any fur-
ther proteinase K treatment will not lead to further
improvements.
It is desirable to characterize the DNA content of indi-
vidual cells’ amplification of the genome without loss of
representation of the original DNA. A variety of kits for
DNA amplification are commercially available and can
be divided into isothermal amplification kits (the Phi-29-
based GE GenomiPhi kit or the Qiagen RepliG kit) and
linker adapter based kits such as the Silicon Biosystems
Ampli1 and the Rubicon PicoPLEX series. The first two
have the advantage of a highly user-friendly protocol
with very short hands-on time and low costs. The
Rubicon PicoPLEX kit takes more effort, but is as fast as
the isothermal kits. The Ampli1 kit has the longest
hands-on time and has a protocol that stretches over
three days. In fact, all the possible amplification tech-
niques could be applied on the single-cell sorted
CellSearch CTC. To demonstrate the sorting, amplifica-
tion and sequencing of the single CTC, we adapted the
GE GenomiPhi kit.
The analyzed exomes of the single SKBR-3 cells were
adversely affected by the amplification process but still
contained useful information. If we look at the sharp in-
crease in low or uncovered bases after WGA in all sam-
ples, it is clear that the amplification process itself
causes a large bias. This makes this amplified DNA un-
suitable for quantitative measurements. Furthermore,
the starting amount of one cell and the cell fixation also
have a substantial influence on the final DNA quality. A
part of the variants could be recovered and this could be
increased when combining the DNA of individual ampli-
fied cells.
From Figure 3 it is clear that, within the same samples,
there was a large difference in the number of detected
cells in CellSearch and the subsequent number of CTC
detected using FACS. It could be that the cells were lost
due to their fragility, in turn due to the permeabilization
process in the CellSearch protocol or by nonspecific
sticking of the cells to surfaces of pipettes and the tube.
Furthermore, CTC that are connected to a leukocyte
might miss the CTC gate due to the level of CD45 APC
staining being too high. We learned from earlier studies
that a variable number of CTC in patients are apoptotic
[8] and the effect of this process on the genomic se-
quence needs to be investigated. The amplification
method of choice described in this paper is just one of
many available methods. The method used depends on
Swennenhuis et al. Genome Medicine 2013, 5:106 Page 10 of 11
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data that are required. The differences between these
kits and the most optimal kit for single-cell CTC DNA
amplification are yet to be determined.
Conclusions
We have shown that CTC enriched by the CellSearch
system can be single-cell-sorted by FACS, and the DNA
retrieved and amplified with an overall efficiency of 20%.
From patient samples that were positive for CTC, it was
possible to sort and amplify 20.6% of the CTC found in
CellSearch. Analysis of sequencing data shows that
GenomiPhi-amplified DNA can be used for variant call-
ing, but not for quantitative measurements. Close to
45% of the exome of single cells can be successfully
sequenced to 20× depth, making it possible to call 72%
of the variants. Overall, coverage was reduced to 30% at
20× depth making it possible to call 56% of the variants
in CellSave-fixed tumor cells.
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